Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Journal of Enzyme Inhibition and Medicinal Chemistry called TNP and its analogs: Modulation of IP6K and CYP3A4 inhibition, Author is Lee, Seulgi; Park, Bernie Byeonghoon; Kwon, Hongmok; Kim, Vitchan; Jeon, Jang Su; Lee, Rowoon; Subedi, Milan; Lim, Taehyeong; Ha, Hyunsoo; An, Dongju; Kim, Jaehoon; Kim, Donghak; Kim, Sang Kyum; Kim, Seyun; Byun, Youngjoo, which mentions a compound: 5451-40-1, SMILESS is C2=NC1=C(C(=NC(=N1)Cl)Cl)[NH]2, Molecular C5H2Cl2N4, Quality Control of 2,6-Dichloropurine.
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biol. processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P 450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesized 15 TNP analogs. Structure-activity relationship and biochem. studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound can be a tool mol. for structural optimization of purine-based IP6K inhibitors.
Here is a brief introduction to this compound(5451-40-1)Quality Control of 2,6-Dichloropurine, if you want to know about other compounds related to this compound(5451-40-1), you can read my other articles.
Reference:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem